LOS ANGELES, May 3, 2018 /PRNewswire/ -- CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced that
its Board of Directors has approved the appointment of Eric L. Curtis, MBA, to the Company's executive
management team, as President and Chief Operating Officer,
effective today.
Mr. Curtis brings 25 years of life science leadership experience
to CytRx, with a proven track record in oncology and orphan
diseases, including the development and commercialization of
several approved and marketed cancer drugs such as Votrient®,
Doxil®, Velcade®, Benlysta® and Tykerb®. Most recently, he
has provided strategic consultancy services to a variety of
healthcare-focused companies, including CytRx. Mr. Curtis'
appointment strengthens the executive leadership team and adds
significant development and operational expertise. He had
previously served as strategic advisor to executive management for
the Company's internal development efforts and external partner
relationships.
"Over the past few months I have witnessed the transformative
capability of CytRx's LADRTM technology to redesign
current cancer treatment paradigms," said Mr. Curtis. "As President
and Chief Operating Officer, I will dedicate my attention to the
partnering of the LADR™ technology and assets, advancing the
Company's current programs and future drug candidate discoveries
for the benefit of all of our shareholders. I intend to
utilize my significant professional experience and relationships to
maximize the success of our scientific programs and execute on
CytRx's mission of bringing new treatment options to patients
battling cancer."
Before joining CytRx, Mr. Curtis served as President, U.S.
Commercial at Aegerion Pharmaceuticals (now Novelion Therapeutics),
where he was instrumental in designing and implementing the
division's structure and business strategy. Prior to Aegerion, Mr.
Curtis served as Vice President and General Manager – Rare
Disease/Cardiopulmonary Business Unit at Bayer Healthcare, where he
successfully led the design and build of this new US commercial
business unit. Prior to Bayer, he held positions of increasing
responsibility at GlaxoSmithKline, culminating in his role as Vice
President, Marketing and Global Commercial Leader, Rare Disease
Business Unit. In this role, he led the successful US launch
of Benlysta®. Prior to that role he was active in designing the
development strategy for Votrient® for the treatment of soft tissue
sarcoma, renal cell carcinoma and other tumor types. Mr.
Curtis also brings substantial sales and marketing acumen gained
through his involvement in several oncology treatments, including
Doxil®, Velcade®, and Tykerb®. Mr. Curtis earned a Master of
Business Administration degree from Pennsylvania State University, as well as a
Bachelor of Science degree from the University
of Pittsburgh, where he majored in both Business and
Psychology.
About CytRx Corporation
CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical company
specializing in research and clinical development of novel
anti-cancer drug candidates that employ linker technologies to
enhance the accumulation and release of drug at the tumor. CytRx is
also rapidly expanding its pipeline of ultra-high potency oncology
candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated
Drug Release) technology platform, a discovery engine designed to
leverage CytRx's expertise in albumin biology and linker technology
for the development of a new class of potential breakthrough
anti-cancer therapies. Aldoxorubicin, CytRx's most advanced
drug conjugate, is an improved version of the widely used
anti-cancer drug doxorubicin and has been out-licensed to NantCell,
Inc.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to the ability of NantCell, Inc., to obtain
regulatory approval for its products that use aldoxorubicin; the
ability of NantCell, Inc., to manufacture and commercialize
products or therapies that use aldoxorubicin; the amount, if any,
of future milestone and royalty payments that we may receive from
NantCell, Inc.; our ability to develop new ultra-high potency drug
candidates based on our LADR™ technology platform; and other risks
and uncertainties described in the most recent annual and quarterly
reports filed by CytRx with the Securities and Exchange Commission
and current reports filed since the date of CytRx's most recent
annual report. All forward-looking statements are based upon
information available to CytRx on the date the statements are first
published. CytRx undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-corporation-names-eric-l-curtis-as-its-president-and-chief-operating-officer-300641857.html
SOURCE CytRx Corporation